Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606709 | 1.00 | TSHR (0.36) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL6227435 | 1.00 | TSHR (0.36) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL8231165 | 0.77 | TSHR (0.35) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL93137 | 0.76 | ALDH1A1 (0.38) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL16583132 | 0.76 | TSHR (0.38) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL8187643 | 0.74 | ALDH1A1 (0.36) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL28473558 | 0.74 | ALDH1A1 (0.36) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL7895364 | 0.74 | KDM4E (0.41) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL11289286 | 0.74 | CYP2C19 (0.52) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL8899156 | 0.73 | TSHR (0.37) | TSHRALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | claimed |
| JP-6336473-A | — | — | None | — | — | JP | disclosed |
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-07-24 | — | — | US | disclosed |
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-11-23 | — | — | US | disclosed |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-09-07 | — | — | US | disclosed |
| US-7091219-B2 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-08-15 | — | — | US | disclosed |
| US-7045518-B2 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-05-16 | — | — | US | disclosed |
| EP-1586558-A2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors | G.D. Searle LLC. (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2001032847-A9 | NOVEL ESTERASES DERIVED FROM PSEUDOMONAS AERUGINOSA, ITS GENE AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CARBOXYLIC ACIDS USING THEM | KOREA RES INST OF BIOSCIENCE (KR) | 2005-07-28 | — | — | WO | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| US-4857469-A | SELECTIVE HYDROLYSIS WITH CULTURED PRODUCT OF TREATED PRODUCT OF MICROORGANISM | TOYO JOZO CO., LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| US-4629701-A | USING A HYDROLASE OR HICROORGANISM IN A CULTURE | MITSUBISHI RAYON COMPANY, LIMITED (JP) | 1986-12-16 | — | — | US | disclosed |
| US-4585595-A | RESOLUTION OF RACEMIC MIXTURES | OCE-ANDENO B.V. (NL) | 1986-04-29 | — | — | US | disclosed |
| US-4356118-A | Tryptophan derivatives | G. D. SEARLE & CO. (US) | 1982-10-26 | — | — | US | disclosed |
| EP-0008833-B1 | OPTICALLY ACTIVE DERIVATIVES OF MERCAPTOISOBUTYRIC ACID AND A PROCESS FOR PREPARING THEM | Océ-Andeno B.V. (NL) | 1981-12-30 | — | — | EP | disclosed |
| EP-0008833-A1 | Optically active derivatives of mercaptoisobutyric acid and a process for preparing them | Océ-Andeno B.V. (NL) | 1980-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | PRSS1, DNPEP, PREP | TSHR 4736/4885ALDH1A1 2674/4885CYP2D6 1662/4885 |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | PRSS1, DNPEP, PREP | TSHR 4736/4885ALDH1A1 2674/4885CYP2D6 1662/4885 |
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | TSHR 4711/4885ALDH1A1 3190/4885CYP2D6 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.